Verrica Pharmaceuticals VRCA Stock
Verrica Pharmaceuticals Price Chart
Verrica Pharmaceuticals VRCA Financial and Trading Overview
| Verrica Pharmaceuticals stock price | 0.42 USD |
| Previous Close | 6.34 USD |
| Open | 6.4 USD |
| Bid | 0 USD x 3200 |
| Ask | 0 USD x 1200 |
| Day's Range | 6.22 - 6.51 USD |
| 52 Week Range | 1.79 - 8.7 USD |
| Volume | 137.64K USD |
| Avg. Volume | 154.8K USD |
| Market Cap | 262.41M USD |
| Beta (5Y Monthly) | 1.996883 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.48 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12 USD |
VRCA Valuation Measures
| Enterprise Value | 203.91M USD |
| Trailing P/E | N/A |
| Forward P/E | -7.9367085 |
| PEG Ratio (5 yr expected) | 0.08 |
| Price/Sales (ttm) | 30.37887 |
| Price/Book (mrq) | 4.047773 |
| Enterprise Value/Revenue | 23.606 |
| Enterprise Value/EBITDA | -9.953 |
Trading Information
Verrica Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.996883 |
| 52-Week Change | 178.66% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 8.7 USD |
| 52 Week Low | 1.79 USD |
| 50-Day Moving Average | 6.1 USD |
| 200-Day Moving Average | 4.72 USD |
VRCA Share Statistics
| Avg. Volume (3 month) | 154.8K USD |
| Avg. Daily Volume (10-Days) | 165.22K USD |
| Shares Outstanding | 41.85M |
| Float | 17.69M |
| Short Ratio | 17.11 |
| % Held by Insiders | 39.93% |
| % Held by Institutions | 23.73% |
| Shares Short | 2.04M |
| Short % of Float | 9.86% |
| Short % of Shares Outstanding | 4.86% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -261.70% |
| Operating Margin (ttm) | -242.82% |
| Gross Margin | -35.51% |
| EBITDA Margin | -237.18% |
Management Effectiveness
| Return on Assets (ttm) | -18.69% |
| Return on Equity (ttm) | -50.088% |
Income Statement
| Revenue (ttm) | 8.64M USD |
| Revenue Per Share (ttm) | 0.23 USD |
| Quarterly Revenue Growth (yoy) | -91.40% |
| Gross Profit (ttm) | 8.31M USD |
| EBITDA | -20488000 USD |
| Net Income Avi to Common (ttm) | -22606000 USD |
| Diluted EPS (ttm) | -0.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 59.95M USD |
| Total Cash Per Share (mrq) | 1.43 USD |
| Total Debt (mrq) | 1.45M USD |
| Total Debt/Equity (mrq) | 2.24 USD |
| Current Ratio (mrq) | 23.873 |
| Book Value Per Share (mrq) | 1.549 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -14900000 USD |
| Levered Free Cash Flow (ttm) | 31.95M USD |
Profile of Verrica Pharmaceuticals
| Country | United States |
| State | PA |
| City | West Chester |
| Address | 44 West Gay Street |
| ZIP | 19380 |
| Phone | 484 453 3300 |
| Website | https://www.verrica.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 22 |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Q&A For Verrica Pharmaceuticals Stock
What is a current VRCA stock price?
Verrica Pharmaceuticals VRCA stock price today per share is 0.42 USD.
How to purchase Verrica Pharmaceuticals stock?
You can buy VRCA shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Verrica Pharmaceuticals?
The stock symbol or ticker of Verrica Pharmaceuticals is VRCA.
Which industry does the Verrica Pharmaceuticals company belong to?
The Verrica Pharmaceuticals industry is Biotechnology.
How many shares does Verrica Pharmaceuticals have in circulation?
The max supply of Verrica Pharmaceuticals shares is 91.78M.
What is Verrica Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Verrica Pharmaceuticals PE Ratio is now.
What was Verrica Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Verrica Pharmaceuticals EPS is -1.48 USD over the trailing 12 months.
Which sector does the Verrica Pharmaceuticals company belong to?
The Verrica Pharmaceuticals sector is Healthcare.
Verrica Pharmaceuticals VRCA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}